Mouth Dissolving Tablets: A Comprehensive Review on Technologies, Research, Patents, and Marketed Products.

The oral route of administration is currently the gold standard in pharmaceuticals, valued for its safety, patient compliance, and economic advantages, which contribute to its high patient compliance. MDTs' format enables them to disintegrate or dissolve rapidly in the mouth, through the incorporation of super disintegrants, such as croscarmellose sodium, sodium starch glycolate, and crospovidone, which act through mechanisms including swelling, wicking (capillary action), and deformation recovery, eliminating the need for water and making it easier to take medications. Such tablets disintegrate or dissolve in saliva in less than 60 seconds. The formulation's popularity and utility led to the creation of multiple MDT technologies. MDTs are a valuable alternative for patients with dysphagia, offering improved reliability and ease of use for children, the elderly, and mentally ill patients. The Pharmaceutical market has seen a rise in fast-dissolving products, with many new launches in the past 2 to 3 years. This growth is also reflected in the increasing use of fast-dissolving technology for new drug development. This article provides an overview of key attributes, benefits, limitations, formulation considerations, technological approaches, assessment methods, and prospects.